Navigation Links
Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
Date:11/8/2007

- Conference Call and Webcast on November 9 at 8:00 a.m. PST -

SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today reported financial results for the three and nine months ended September 30, 2007.

"Halozyme's unique capabilities in navigating the complexities of the extracellular matrix provide a number of exciting opportunities to build shareholder value," said Jonathan Lim, MD, Halozyme's President and CEO. "Building on our track record for accelerated development and commercialization and leveraging the franchises of our partners, we continue to pursue these opportunities by executing our Enable, Improve and Innovate programs. The Enable program focuses on making our partners' drugs better by potentially improving administration, extending product lifecycles, and increasing patients' compliance, and includes HYLENEX recombinant (hyaluronidase human injection) and our Enhanze(TM) Technology for drug delivery. In this regard, we are very pleased that we recently broadened our relationship with Baxter to apply our Enhanze Technology to their GAMMAGARD product. We are also excited about developing our own products through the Improve program, which focuses on co-formulations of rHuPH20 with marketed small molecules, particularly oncology and bisphosphonate drugs; and the Innovate program, which focuses on developing new molecular entities targeting the extracellular matrix with some exciting projects underway in oncology and dermatology."

Third Quarter 2007 Highlights

-- The completion of a new agreement with Baxter International Inc. to

a
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... The shortlist of contenders for the highest ... narrowed tonight as the winners of the Siemens ... Finals were announced.  Cancer stem cell research earned ... Angela Zhang of Cupertino, California.  Research on molecular ...
... working at Argonne National Laboratory,s (ANL) Center for Nanoscale ... into nanowires, boosting the material,s functionality and providing potential ... led by Anirudha Sumant, a materials scientist at ANL, ... & Exhibition, held Oct. 30 Nov. 4, 2011, ...
... Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of ... that all six proxy resolutions passed at a special ... statement was filed with the Securities and Exchange Commission ... and on the Company,s web site:   www.radient-pharma.com ...
Cached Biology Technology:Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 2Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 3Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 4Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 5Scientists carve nanowires out of ultrananocrystalline diamond thin films 2Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders 2
(Date:12/11/2014)...  That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ...
(Date:12/10/2014)... a leader in performance biometric data sensor technology, today ... licensees for highly accurate, clinically validated biometric technology. This ... fitness and health sectors, but first responders/military and gaming ... as useful as the biometric data it delivers. As ...
(Date:12/10/2014)... Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) has announced the ... report to their offering. ... and smart cards for projects such as rural banking ... the major trends witnessed in the market. Besides the ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... Tumor metastasis, the ability of cancer cells to migrate from ... accounts for over 90% of cancer deaths. When patients die ... by malignant cells that split off from the primary cancer ... the Ludwig Center at the University of Chicago hypothesized over ...
... School of Medicine and AstraZeneca, a global biopharmaceutical company, ... 2a trial to assess the effectiveness of AZD5847, a ... patients with HIV co-infection. The study is sponsored ... (NIAID), part of the U.S. National Institutes of Health. ...
... 2002-2003 was short-lived, but a novel type of human coronavirus ... humans and bats alike, a fact that could make the ... to be published in in mBio , the online ... 11. The new coronavirus, called hCoV-EMC, is blamed for five ...
Cached Biology News:Predictors of cancer disease progression improve patient selection for metastasis-directed therapy 2New tuberculosis drug trial begins in South Africa 2New coronavirus has many potential hosts, could pass from animals to humans repeatedly 2New coronavirus has many potential hosts, could pass from animals to humans repeatedly 3
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
Request Info...
Biology Products: